AIM: To investigate primarily the prognostic value of Ki-67 as well as other parameters in gastrointestinal stromal tumors (GISTs). parameters investigated in this study included tumor size cell type (pure spindle pured epitheloid mixed spindle and epitheloid) mitotic count hemorrhage necrosis mucosal ulceration. Clinical data included age gender primary tumor location and spread of disease. χ2 test and Student’s = 0.06). Analysis of time to progression/relapse in initially localized disease (univariate analysis) tumor size mitotic count Ki-67 and type of d-KIT distribution (cytoplasmic membrane/”dot-like”) showed statistically significant correlation. In multivariate analysis in the group of patients with localized disease there were only 2 parameters that have impact on relapse Ki-67 and SMA (< 0.0001 and < 0.034 respectively). Furthermore Ki-67 was analyzed in localized disease localized with recurrence and metastatic disease. It was shown that there is a stringent difference between these 2 sets of individuals (median worth was 2.5 for localized disease 10.0 for recurrent/metastatic disease < 0.0001). It had been also shown how the cut-off worth which continues to be statistically significant with regards to relapse on the amount of 6%. The curves for success on that cut-off level are considerably different (< 0.04 Cox F). Summary: Ki-67 presents a substantial prognostic element for GIST recurrence that could become of great importance in analyzing malignant potential of disease. < 0.05. All statistical evaluation were performed from the statistical bundle statistica. Outcomes Our research comprised 100 GIST individuals. Mean individuals’ age group was 60.5 (range 20-78) years; 56% of individuals were men. Individual distribution in three organizations relating to age group and sex can FS be demonstrated in Desk ?Desk1.1. There have been 36 individuals presenting primarily with localized disease 29 got localized disease additional with recurrence and 35 got metastatic disease from the starting. Tumors originated mostly in the abdomen (41%) the tiny intestine was the next most common area (36%) in 8% digestive tract and rectum and Axitinib in 5% retroperitoneum was included. In 10% of instances major Axitinib site of GIST had not been clearly determined due Axitinib to the endemic of the condition. The mean size of major tumors (in individuals without metastases) was 6.5 cm and 35 patients got distant metastases in the right time of diagnosis. Metastases were most localized in the liver organ all the sites were rarely involved often. The mean duration of follow-up was Axitinib 60 (range 28-110) mo. Survival curve for all patients included in our study is shown in Figure ?Figure1.1. Further on multiple parameters were analyzed for their effect on overall survival in all patients (Table ?(Table2).2). Most of them showed no effect more precisely only 2 parameters are close to statistically significant prediction of outcome and biological behavior on the level of = 0.06. These are Ki-67 Axitinib and type of distribution of c-KIT. On the contrary when we analyzed time to progression/relapse in localized disease in univariate analysis tumor size mitotic rate Ki-67 and type of c-KIT distribution (cytoplasmic membrane/“dot-like“) showed statistically significant correlation. In multivariate analysis in the group of patients with localized disease there were only 2 parameters that have impact on relapse Ki-67 and SMA expression (Table ?(Table3).3). Furthermore when we compared Ki-67 in three different patients group it was obvious that there is a strict difference between mean value of Ki-67 in localized disease recurrent and metastatic disease together (median in localized disease was 2.5 10.0 in recurrent and metastatic disease < 0.0001). It was shown that the cut-off value which is still statistically significant in terms of relapse on the level of 6% (Figure ?(Figure2).2). Also it has been shown that the curves for survival on that cut-off level are significantly different (= 0.04 Cox =100) Figure 2 Value of Ki-67 in three different groups of patients. Table 3 Multivariate analysis Axitinib of different parameters for the disease free interval in patients with initially localized disease (= 65) Figure 3 Survival curves with different values of Ki-67 (cut-off on.